Eli Lilly to present eloralintide-tirzepatide combination data on September 30
The mid-stage readout at a European Association for the Study of Diabetes symposium enrolls adults with obesity or overweight and type 2 diabetes.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 18 17:15 ETSource: 24/7 Wall St.
The wire
- 01Lilly presents Phase 2 data on eloraTZP, combining amylin analog eloralintide with tirzepatide, at an EASD symposium on September 30; a Phase 1 study suggested deeper weight loss than tirzepatide alone.
- 02Prescribers and operators watching amylin combinations will look at dose-response separation from tirzepatide monotherapy, tolerability and discontinuation rates, not just placebo comparisons.
- 03Framing comes from an investment commentary rather than the company; Lilly guides full-year revenue to $85.0 billion to $87.0 billion and targets a retatrutide BLA in Q1 2027.
From the source
Read at 247wallst.comCan Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?
Eli Lilly stakes its trillion-dollar valuation on mid-stage data for a two-drug obesity combo, and the September 30 readout will reveal whether eloraTZP is a genuine franchise leap or an expensive gamble on incremental gains.